Specific types of human papillomavirus (HPV) are known to play a causal role in cervical cancer (NIH, 1996) . Cervical cancer is the second most common cancer in women worldwide (Bosch et al., 1995) . In developing countries, cervical cancer is the most common cancer, due to the lack of proper screening practices, encouraging the development of an effective prophylactic vaccine. The development of an HPV vaccine has been significantly hindered by the difficulty of HPV propagation in culture (Lowy et al., 1994) . However, HPV virus-like particles (VLP) produced by baculovirus expression in insect cells (Kirnbauer et al., 1992 ; Hagensee et al., 1993 ; Rose et al., 1993) are emerging as the immunogen of choice for prophylactic HPV vaccines (Kirnbauer, 1996) . Several studies have shown that papillomavirus VLP elicit high titres of neutralizing antibodies in serum and protection from experimental challenge with infectious virus in animal papillomavirus models (Breitburd et al., 1995 ; Kirnbauer et al., 1996 ; Suzich et al., 1995) . Immunization of cottontail rabbits with VLP composed of the cottontail rabbit papillomavirus (CRPV) L1 major capsid protein has recently been shown to protect rabbits against CRPV challenge (Breitburd et al., 1995 ; Christensen et al., 1996 ; Jansen et al., 1995) . In a canine oral papillomavirus model, neutralizing antibodies have been shown to confer protection from infection with canine oral papillomavirus (Suzich et al., 1995) . A tumour cell challenge model reported by De Bruijn et al. (1998) has demonstrated the therapeutic effect of HPV-16 VLP (VLP-16) immunization. The role of cell-mediated immunity in the control of papillomavirus infection is not well established. Several clinical and experimental studies have shown, however, that cell-mediated immune responses play a role in both susceptibility to and regression of HPV infections (Coleman et al., 1994 ; Frazer et al., 1986 ; Alloub et al., 1989) . Several recent studies in mice have shown that VLP are also capable of priming a productive cellmediated immune response. This response is associated with the production of Th " -type cytokines and the delivery of HPV antigens to the HLA class I processing pathway for priming of cytolytic CD8 + T cells (Peng et al., 1998 ; Dupuy et al., 1997).
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HPV vaccine development has been further impaired by the inability to infect laboratory animals with HPV. This has prevented the demonstration of protection against HPV challenge. The present study describes the development and use of a recombinant HPV-16 L1-vaccinia virus (VV) challenge model in mice to demonstrate protection in VLP-16-vaccinated mice and to investigate the importance of cell-mediated immunity induced by VLP-16. The use of recombinant VV expressing the nucleoprotein of vesicular stomatitis virus as a challenge system was first described by Bachmann et al. (1994) to investigate the efficacy of a potential vesicular stomatitis virus vaccine. This technique has also been applied to assess human immunodeficiency virus type 1 vaccine regimes in mice (Belyakov et al., 1998 ; Kent et al., 1998) . The present study shows that immunization with VLP-16 elicits T cell proliferative responses characterized by the production of both Th " and Th # cytokines and is capable of protecting mice against challenge with recombinant HPV-16 L1-VV (VVL1 R -16).
Table 1. IFN-γ and IL-4 production after HPV-16 L1-VLP immunization
Peak cytokine production was measured in supernatants after 6 days in vitro stimulation. IL-4 production was not detected at earlier time-points. The detection limits of the assays were 47 pg\ml for IFN-γ and 15 pg\ml for IL-4.
IFN-γ (pg/ml)
IL-4 (pg/ml) VLP-16 were produced in a baculovirus expression system (Rose et al., 1994 b) . To examine the T cell response to VLP-16, groups of 6-8-week-old BALB\c mice (Animal Unit, University of Cape Town) were immunized intraperitoneally (i.p.) either with a single dose of 20 µg VLP-16 or with three consecutive weekly doses of 10 µg VLP-16. Two weeks after the last inoculation, splenocytes were isolated by passage through a steel mesh (Sigma) to obtain a single-cell suspension. Contaminating red blood cells were removed by centrifugation over Ficoll-Hypaque density gradients as described previously (Boyum, 1968) . Viable cells were resuspended at 2i10' cells\ml in RPMI-1640 medium supplemented with 10 % foetal calf serum. For the lymphoproliferation assay, splenocytes (2i10& cells per well) were seeded in triplicate into roundbottomed 96-well culture plates (Nunc). Splenocytes were incubated for 6 days at 37 mC in a humidified 5 % CO # atmosphere in the presence of purified VLP-16 (15 µg\ml) or baculovirus-insect cell extract (10 % v\v). [$H]Thymidine (1 µCi per well) was added to each well for the last 18 h of the assay. The cells were harvested by using an automated cell harvester (PHD, Cambridge Technology) and the radioactivity was measured by using a liquid scintillation counter (Tricarb-4640). For generation of cytokine-containing supernatants, splenocytes (2i10& cells per well) were seeded in quadruplicate into round-bottomed 96-well culture plates (Nunc) in the presence or absence of purified VLP-16 (15 µg\ml). Culture supernatants were collected at 4, 5 and 6 days and stored at k20 mC. Interferon (IFN)-γ (Th " -type) and interleukin (IL)-4 (Th # -type) were assessed by a sandwich ELISA according to the manufacturer's recommendations (Biotrak, Amersham).
A single i.p. immunization of 20 µg VLP-16 resulted in detectable T cell proliferation after only a single cycle of in vitro stimulation (Fig. 1 a) . When mice were given three consecutive weekly booster doses, proliferative responses to VLP-16 were increased 12-fold (Fig. 1 b) . Because the VLP were purified from a baculovirus expression system, insect cell extract was used as CEHC a control for non-specific proliferation to residual insect cell proteins. Lymphocytes from VLP-16-primed mice did not proliferate in response to these insect cell proteins, indicating that the response to VLP-16 was antigen-specific. Lymphocytes from control mice, given placebo inoculations with PBS, did not proliferate to HPV antigen or insect cell proteins.
The supernatants from splenocyte culture were examined for the presence of Th " -type (IFN-γ) or Th # -type (IL-4) cytokines (Table 1) . Although low levels of IFN-γ (215 pg\ml) were detectable after a single immunization with VLP-16, IFN-γ levels were significantly boosted (6-fold) after the three consecutive immunizations (1349 pg\ml). Low levels of IL-4 were also detected after VLP-16 inoculation (128 pg\ml). Control mice immunized with PBS alone showed no detectable cytokine production in response to VLP-16.
In order to evaluate the protective effects induced by VLP-16-specific cell-mediated immunity, a recombinant VV-HPV-16 L1 challenge model was developed. The use of recombinant VV challenge allows selective evaluation of cell-mediated rather than neutralizing antibody immune mechanisms because VV recombinants do not express the transfected gene products in their envelope in a form that is directly accessible to antibodies (Zinkernagel et al., 1990) . Further reports have confirmed that resistance to challenge with recombinant VV was mediated predominantly by CD8 + T cells (Binder & Kundig, 1991) . The Western Reserve (WR) strain of VV was used, which causes disseminating infection in mice, with the highest titres of virus being measured in the ovaries (Binder & Kundig, 1991) . The L1 gene of HPV-16 (Rochester strain), which was obtained from W. Bonnez , had been cloned as described by Rose et al. (1993 and White et al. (1998) . This gene was cloned into the SmaI site of pMos blue and then further subcloned into the SalI\SmaI sites of the VV shuttle vector pSC65 downstream of the synthetic early\late promoter (PE\L), generating pSC65L1-16 R. This vector introduces the L1 gene into the thymidine kinase (TK) site of VV and also contains the β-galactosidase gene for the visual selection of blue recombinant plaques (Chakrabarti et al., 1985) . VV (strain WR) was propagated in eggs and purified as described by Stannard et al. (1998) . CV-1 and human TK − 143 cells were grown in DMEM with 10 % foetal bovine serum. CV-1 cells were infected with VV at an m.o.i. of 5. The virus was removed 1 h later and the cells were transfected with plasmid DNA by using DOTAP (Boehringer) according to the manufacturer's instructions. For blue plaque identification, staining with X-Gal (35 µg\ml) was performed in agarose overlay. TK − recombinants were isolated by plaque assay in the presence of 5-bromo-2'-deoxyuridine (0n5 mg\ml) and designated VVL1 R -16.
Two groups of four female BALB\c mice (8-12 weeks old) were compared. Group A was vaccinated with 10 µg VLP-16 (Bachmann et al., 1994) and group B was not vaccinated. After 13 days, groups A and B were challenged with VVL1 R -16. Five days after challenge, the ovaries were harvested. The ovaries were chopped finely, placed in McIlvain's buffer (4 mM citric acid, 0n2 M Na # HPO % .12H # O) (100 mg ovary\ml) and homogenized by using a ten Broeck grinder (30 strokes). This was followed by three cycles of freeze-thawing and then preparations were centrifuged at 2000 r.p.m. for 5 min. The supernatant fluid was titrated in CV-1 cells and the VVL1 R -16 titre per mouse was calculated.
VLP-16-immunized BALB\c mice were better able to control VVL1 R -16 infection following challenge than the unvaccinated control mice (4n6 log "! protection, P 0n05 ; Fig. 2 a) . Protection was VLP-16-specific, as challenge with wild-type VV only resulted in a 1 log "! reduction in vaccinated mouse ovarian virus titre (2n4i10( p.f.u.) compared with unvaccinated mice (2n3i10) p.f.u.). X-Gal staining of titration plates containing virus from mouse ovaries confirmed that uncleared virus in vaccinated mice was recombinant VVL1 R -16. A similar experiment with VLP-16-immunized C57 BL\6 mice confirmed that they were also protected from VVL1 R -16 challenge compared with their unvaccinated littermates (2n3 log "! protection) but the level of protection was lower compared with BALB\c mice (Fig. 2 b) . This finding is consistent with previous reports that have shown that C57 BL\6 mice are genetically more resistant to pox virus infection CEHD D. Marais and others D. Marais and others than the innately susceptible BALB\c strain (O'Neill & Brenan, 1987) . These results indicate that BALB\c mice may be a better strain for the VVL1 R -16 challenge model. This study has demonstrated that the immunization of mice with VLP-16 produces a protective T cell response characterized by the production of both Th " and Th # cytokines and affords protection against challenge from VVL1 R -16. The ability to titrate VV in ovaries offers a quantitative measure of protective immunity induced in mice by potential HPV prophylactic vaccines. Current studies are examining whether there is cross-protection between HPV VLP types and the relative advantages of different routes of VLP vaccine administration and virus challenge. These results confirm others indicating that VLP are efficient candidates for a prophylactic vaccine.
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